Queen’s leading new research aimed at improving outcomes for early-stage bowel cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers from the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast are leading an international consortium that aims to determine better ways to treat patients diagnosed with the earliest stages of bowel cancer.

The consortium is funded by Cancer Research UK.

The consortium includes a multi-disciplinary team of research scientists and clinicians from across the UK and Europe and is led by Philip Dunne, molecular pathologist at the Patrick G Johnston Centre for Cancer Research.

There are approximately 1.4 million cases of bowel cancer diagnosed worldwide every year and the introduction of the bowel cancer screening program for people over the age of 60 has led to a significant increase in the proportion of patients who are diagnosed with early-stage cancers.

Survival rates for patients diagnosed at the earliest stage of bowel cancer are in excess of 95%, but only in a small proportion of cases, screening identifies patients with highly aggressive tumors. This presents a major challenge in the clinic, as current diagnostic techniques are unable to distinguish these aggressive tumors that require more extensive in-patient treatment, from patients with less aggressive tumors that can be treated as outpatients.

“This new project aims to use state of the art molecular technologies to identify for the first time the underlying biology of these aggressive born-to-be-bad tumors,” Dunne said in a statement. “This information can be used to develop clinical biomarkers of aggressive disease that can be used to guide treatment decision making for patients in the future.”

The bowel cancer screening program is freely available to everyone over the age of 60, with a test being sent to your home every two years. The test is designed for people who have no symptoms and can detect very early signs of bowel cancer, sometimes up to 10 years before the development of advanced disease.

In a lot of cases the screening test can identify non-cancerous polyps in the bowel, which, if left unchecked, may become cancerous over time.

“Our consortium aims to improve our understanding of how these tumors grow and develop, with results being used to guide the development of clinical trials in the near future,” Maurice Loughrey, consultant pathologist at the Belfast Health and Social Care Trust and co-investigator within the consortium, said in a statement.

The initial phase of the Cancer Research UK-funded project will run until 2023, and work has already begun to collect clinical samples from across Europe to be centralised in Belfast for molecular profiling and analysis. Following this initial phase, the teams of scientists will continue to collect and analyse data over the coming years to ensure that clinicians have as much information as possible to inform treatment decisions.

“This work will provide us with the largest known collection of early-stage bowel cancer samples, which will serve as an important resource for scientists worldwide to investigate this disease,” Keara Redmond, researcher from the Patrick G Johnston Centre for Cancer Research at Queen’s, scientific specialist and project manager in Belfast, who will lead the molecular profiling, said in a statement. “This will enable the field to identify changes in tumor DNA, both mutations and gene activation, associated with aggressive disease.”

While the bowel cancer screening program has been significantly affected due to COVID-related delays, it remains an important tool for preventing deaths from bowel cancer.

In This Issue


President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...